Bibliografía levetiracetam

 Beasley, M.J. y Boothe, D. M. (2012), “The pharmacokinetics of single dose

extended release Keppra with and without food in healthy adults dogs”,
ACVIM Forum Abstract Proceeding, 26 (3), pp. 819.

 Beasley, M.J. y Boothe, D. M. (2015), “Disposition of extended reléase

levetiracetam in normal healthy dogs after single oral dosing”, Journal of
Veterinary International Medicine, 29, pp. 1348-1353.

 Berkovic, S. F., Knowlton, R. C., Leroy, R. F., Schiemann, J. y Falter, U. (2007)

“Placebo-controlled study of levetiracetam in idiophatic generalized epilepsy”,
Neurology, 69, pp.1751-1760.

 Biddick, A.A., Bacek, L.M. y Taylor, A.R. (2018), “A serious adverse event
secondary to rapid intravenous levetiracetam imjection in a dog”, Journal of
Veterinary Emergency and Critical Care, 28 (2), pp.157-162.

 Boozer, L. B., Platt, S. R., Haley, A. C., Linville, A. V., Kent, M., Barron, L. E.,
Nie, B., Arnold, R. D. (2014), “Pharmacokinetic evaluation of immediate- and
extended-release formulations of levetiracetam in dogs”, American Journak of
Veterinary Research, 76 (8), pp. 719-723.

 Cagnotti, G., Odore, R., Gardini, G., Amedeo, S., Bertone, I., Guerriero, G.,
Lentini, L., Dappiano, E. y D´Angelo, A. (2018), “Pharmacokinetics of rectal
levetiracetam as add-on treatment in dogs affected by cluster seizures or status
epilepticus”, BMC Veterinary Research, 14 (189), pp. 1-6.

 Charalambous, M., Brodbelt, D. y Volk, H. A. (2014), “Treatment in canine

epilepsy- a systematic review”, BMC Veterinary Research, 10 (257), pp. 1-24.
 De Risio, L. (2014c) “Levetiracetam” en De Risio, L. y Platt, S. (eds) Canine
and feline epilepsy diagnosis and management. Oxfordshire: CABI, pp. 425-
439.

 Fryer, K. J., Levine, J. M., Peycke, L. E., Thompson, J. A. y Cohen, N. M.

(2011), “Incidence of postoperative seizures with and without levetiracetam
pretreatment in dogs undergoing portosystemic shunt attenuation”, Journal of
Veterinary Internal Medicine, 25, pp. 1379-1384.

 Hovinga, C. A. (2001), “Levetiracetam: a novel antiepileptic drug”,

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
21, pp. 1375-1388.

 Isoherranen, N., Yagen, B., Soback, S., Roeder, M., Schurig, V. y Bialer, M.
(2001), “Pharmacokinetics of levetiracetam and its enantiomer (R)--ethyl-oxo-
pyrrolidine acetamide in dogs”, Epilepsia, 42 (7), pp. 825-830.

 Komur. M, Okuyaz, C., Celtik, Y., Resitoglu, B., Polat, A., Balci. S., Tamer, L.,
Erdogan, S., Beydagi, H. (2014), “Neuroprotective effect of levetiracetam on
hypoxic ischemic brain injury in neonatal rats” Childs Nerv System, 30,
pp. 1001-1009.

 Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Hauser, W. A.,
Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S. y French, J. (2010),
“Definition of drug resistant epilepsy: consensus proposal by the ad hoc task
force of the ILAE commission on therapeutic strategies”, Epilepsia, 51 (6),
pp. 1069-1077.

 Margineau, D. G. y Klitgaard, H. (2003), “Levetiracetam has no significant

gamma-aminobutyric acid-related effect on paired-pulse interaction in the
dentate gyrus of rats” European Journal of Pharmacology, 466 (3), pp. 255-261.
 Micov, A., Tomić, M., Popović, B. y Stepanović-Petrović, R. (2010), “ The
antihyperalgesuc effect of levetiracetam in an inflammatory model of pain in
rats: mechanism of action”, British Journal of Pharmacology, 161, pp. 384-392.

 Moore, S. A., Muñana, K. R., Papich, M. G. y Nettifee- Osborne, J. (2010),

“Levetiracetam pharmacokinetics in healthy dogs following oral administration
of single and multiple doses”, American Journal of Veterinary Reseach, 71,
pp. 337-341.

 Moore, S.A., Muñana, K.R., Papich, M.G. y Nettifee-Osberne, J. (2010),

“Levetiracetam pharmacokinetics in healthy dogs following oral administration
of single and multiple doses”, American Journa of Veterinary Research, 71(3),
pp. 337-341.

 Moore, S. A., Muñana, K. R., Papich, M. G. y Nettifee-Osborne, J. A. (2011),

“The pharmacokinetics of levetiracetam in healthy dogs concurrently reciving
phenobarbital”, Journal of Veterinary Pharmacology and Therapeutics”, 34,
pp. 31-34.

 Muñana, K. R., Thomas, W. B., Inzana, K. D., Nettifee-Osborne, J. A.,

McLucas, K. J., Olby, N. J., Mariani, C. J. y Early, P. J. (2012), “Evaluation of
levetiracetam as adjuntive treatment for refractory canine epilepsy: a
randomized, placebo-controlled, crossover trial”, Journal of Veterinary Inernal
Medicine, 26, pp. 341-348.

 Noachtar, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W. B. y

Schiemann-Delgado, J. (2008), “Levetiracetam for the treatment of idiopathic
generalized epilepsy with myoclonic seizures”, Neurology, 70, pp. 607-616.

 Packer, R. M. A., Nye, G., Porter, S. E., Vok, H. A. (2015), “Assessment into
the usage of levetiracetam in a canine epilepsy clinic”, BMC Veterinary
Research, 11 (25), pp. 1-8.
 Patsalos, P. N. (2004), “Clinical pharmacokinetics of levetiracetam”, Clin
Pharmacokinet, 43, pp. 707-724.

 Patterson, E. E., Goel, V., Cloyd, J. C., O´Brien, T. D., Fisher, J. E., Dunn, A.,
W. y Leppik, I. E. (2008), “Intramuscular, intravenous and oral levetiracetam in
dogs: safety and pharmacokinetics”, 31, pp. 253-258.

 Podell, M. (2013), “Antiepileptic drug therapy and monitoring”, Topics in

Companion Animal Medicine”, 28 (2), pp.59-66.

 Stienen, M. N., Haghikia, A., Dambach, H., Thöne, J., Wiemann, M., Gold, R.,
Chan, A., Dermietzel, R., Faustmann, P. M., Hinkerohe, D. y Prochnow, N.
(2001) “Anti-inflammatory effects of the anticonvulsant drug levetiracetam on
electrophysiological properties of astroglia are mediated via TGFβ1 regulation”,
British Journal of Pharmacology, 162, pp. 491-597.

 Vidal Vademecum Spain (2010) Vidal Vademecun Spain. Disponible en :

https://www.vademecum.es/medicamentos-principio-activo-
levetiracetam_5054_1 (Accedido: 8 de Enero de 2019).

 Volk, H.A., Matiasek, L. A., Luján Feliu-Pascual, A., Platt, S. R. Y Chandler, K.

E. (2008), “The efficacy and tolerability of levetiracetam in pharmacorresistant
epileptic dogs”, The Veterinary Journal, 176, pp. 310-319.

 Yang, X. F., Weisenfeld, A. Y Rothman, S. M. (2007), “Prolonged exposure to

levetiracetam reveals a presynaptic effect on neurotransmission”, Epilepsia, 48,
pp. 1861-1869.

 Zona, C., Niespodziany, I., Marchetti, C., Klitgaard, H., Bernardi, G. y

Margineau, D. G. (2001), “Levetiracetam does not modulate neuronal voltaje-
gated Na+ and T-type Ca2+ currents”, Seizure, 10 (4), pp. 279-286.